Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin
Imatinib shrank tumours in about a third of patients with melanoma carrying KIT mutations, but only in those with mutations in specific exons, defining a small targetable subgroup among mucosal and acral melanomas.
Overview
Phase 2 study of 25 patients with advanced melanoma with KIT mutations or amplification arising on mucosal, acral or chronically sun-damaged skin treated with imatinib.
Overall response was 29 percent, with durable responses confined to tumours with KIT mutations in exons 11 and 13 (particularly L576P and K642E), and none in tumours with KIT amplification alone; median time to progression was 3.7 months overall.
- Objective response 29 percent overall; responses limited to exon 11 and 13 mutations.
- No responses with KIT amplification without mutation.
KIT testing is worthwhile in mucosal and acral melanoma, and imatinib is a guideline option for exon 11 or 13 mutations after or alongside immunotherapy.
- Small study; KIT mutations occur in under 15 percent of mucosal and acral melanomas.
Similar pages
not linked directly; found by shared links- Key paperSomatic activation of KIT in distinct subtypes of melanoma
Shares Acral melanoma, Mucosal melanoma, Journal of Clinical Oncology.
- Key paperDistinct sets of genetic alterations in melanoma
Shares Acral melanoma, Mucosal melanoma.
- Key paperWhole-genome landscapes of major melanoma subtypes
Shares Acral melanoma, Mucosal melanoma.
- Key paperNivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis
- Key paperAALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children
Shares Journal of Clinical Oncology, Imatinib.
- Key paperKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour
Shares Journal of Clinical Oncology, Imatinib.
- Key paperImatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)
Shares Journal of Clinical Oncology, Imatinib.
- TrialA Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat
Shares Acral melanoma, Mucosal melanoma.